Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Chennai

Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Chennai

Chennai , 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of its new state-of-the-art Regional Reference Laboratory in Chennai, Tamil Nadu. This expansion marks a pivotal moment in Lupin Diagnostics’ commitment to provide accessible, affordable, and quality diagnostic healthcare services in South India. The newly launched laboratory enhances Lupin Diagnostics’ extensive network which now comprises of 36 laboratories and over 600 collection centers across India.

The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies and a team of highly qualified clinical experts. Lupin Diagnostics offers an extensive range of reliable and high-quality diagnostic services, including molecular diagnostics, cytogenetics, flow cytometry, cytology, microbiology, serology, haematology, immunology, routine biochemistry, and more, apart from routine and specialized tests.

In today’s healthcare landscape, evidence-based treatment has become the norm, with diagnostic tests serving as the foundation for nearly 70% of treatment decisions. Lupin Diagnostics prioritizes accuracy and quality by following stringent quality control protocols. Temperature-controlled sample movement ensures the consistent integrity and quality of each sample. With a robust home collection service team and network, Lupin Diagnostics prioritizes patient convenience, allowing real-time tracking of assigned phlebotomists. Additionally, the Company enhances its value-added services with dynamic smart reports, health monitoring tips, and historical trend graphs for patients.

Commenting on the launch, Ravindra Kumar, CEO, Lupin Diagnostics said, “The launch of our state-of-the-art Regional Reference Laboratory in Chennai signifies a significant step toward accessible and reliable healthcare. Our vision extends beyond lab tests; it encompasses a commitment to empowering doctors and patients through precise, evidence-based diagnostics. With cutting-edge technology and a team of dedicated experts, we aim to redefine healthcare experiences, fostering a society where accurate diagnosis is a cornerstone of well-being. This expansion reflects our relentless dedication towards patient-centricity and purpose of being a catalyst for healthier lives.”

Lupin Diagnostics’ unwavering commitment to quality and trust is underscored by the NABL accreditations it has achieved. Within two years of operations, 30% of its laboratories (10 laboratories) have attained NABL accreditation.

Business